Evidence map›Paper›PMID 36920968›Full record

ArticlePloS one2023

"Stabilise-reduce, stabilise-reduce": A survey of the common practices of deprescribing services and recommendations for future services.

Ruth E Cooper, Michael Ashman, Jo Lomani, Joanna Moncrieff, Anne Guy, James Davies, Nicola Morant, Mark Horowitz

Full text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruth E CooperNIHR Mental Health Policy Research Unit, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.ORCID 0000-0002-9735-4731
Michael AshmanDepartment of Life Sciences, University of Roehampton, London, United Kingdom.ORCID 0000-0003-4195-0208
Jo LomaniIndependent Researcher, United Kingdom.
Joanna MoncrieffResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, United Kingdom.
Anne GuyAll-Party Parliamentary Group for Prescribed Drug Dependence, Secretariat 2016-19, 2020-Present, Westminster, United Kingdom.
James DaviesDepartment of Life Sciences, University of Roehampton, London, United Kingdom.
Nicola MorantDivision of Psychiatry, University College London, London, United Kingdom.
Mark HorowitzResearch & Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, United Kingdom.ORCID 0000-0003-1318-2029

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPublic Health England recently called for the establishment of services to help people to safely stop prescribed drugs associated with dependence and withdrawal, including benzodiazepines, z-drugs, antidepressants, gabapentinoids and opioids. NICE identified a lack of knowledge about the best model for such service delivery. Therefore, we performed a global survey of existing deprescribing services to identify common practices and inform service development.

methodsWe identified existing deprescribing services and interviewed key personnel in these services using an interview co-produced with researchers with lived experience of withdrawal. We summarised the common practices of the services and analysed the interviews using a rapid form of qualitative framework analysis.

resultsThirteen deprescribing services were included (8 UK, 5 from other countries). The common practices in the services were: gradual tapering of medications often over more than a year, and reductions made in a broadly hyperbolic manner (smaller reductions as total dose became lower). Reductions were individualised so that withdrawal symptoms remained tolerable, with the patient leading this decision-making in most services. Support and reassurance were provided throughout the process, sometimes by means of telephone support lines. Psychosocial support for the management of underlying conditions (e.g. CBT, counselling) were provided by the service or through referral. Lived experience was often embedded in services through founders, hiring criteria, peer support and sources of information to guide tapering.

conclusionWe found many common practices across existing deprescribing services around the world. We suggest that these ingredients are included in commissioning guidance of future services and suggest directions for further research to clarify best practice.

Indexed as

DeprescriptionsAnalgesics, OpioidAntidepressive AgentsBenzodiazepinesEnglandHumansAnalgesics, OpioidAntidepressive AgentsBenzodiazepines

Identifiers

PMID36920968
PMCPMC10016688

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read45
reference markers read3
identifiers read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.